These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26176068)

  • 1. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria.
    Jiang L; Yan LN; Wen TF; Li B; Yang JY
    Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):494-9. PubMed ID: 24103279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation.
    Oya H; Sato Y; Yamamoto S; Nakatsuka H; Kobayashi T; Hara Y; Waguri N; Suda T; Aoyagi Y; Hatakeyama K
    Transplant Proc; 2006 Dec; 38(10):3636-9. PubMed ID: 17175353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
    de Ataide EC; Garcia M; Mattosinho TJ; Almeida JR; Escanhoela CA; Boin IF
    Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
    Shim JH; Lee HC; Han S; Kang HJ; Yu E; Lee SG
    Liver Transpl; 2013 Mar; 19(3):336-45. PubMed ID: 23203386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
    Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
    Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCC in living donor liver transplantation: can we expand the Milan criteria?
    Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
    Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of preoperative C-reactive protein and alpha-fetoprotein levels for prognostication of patients with hepatocellular carcinoma after living donor liver transplantation.
    Mori S; Choi Y; Park MS; Kim H; Hong G; Yi NJ; Lee KW; Suh KS
    Hepatogastroenterology; 2014; 61(136):2353-8. PubMed ID: 25699382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.